However, because the p16-CDK4/6-Rb axis is deregulated in ∼70% of melanomas [1], our hMELT stable lines provided an excellent backdrop for the discovery of clinically relevant pathways engaged by mitogenic PAK5 mutants. The gene discussed is RB1; the disease is melanoma.